Cargando…

Long-term morbidity and mortality in patients diagnosed with an insulinoma

OBJECTIVE: Insulinomas are rare functional pancreatic neuroendocrine tumours. As previous data on the long-term prognosis of insulinoma patients are scarce, we studied the morbidity and mortality in the Finnish insulinoma cohort. DESIGN: Retrospective cohort study. METHODS: Incidence of endocrine, c...

Descripción completa

Detalles Bibliográficos
Autores principales: Peltola, Elina, Hannula, Päivi, Huhtala, Heini, Metso, Saara, Sand, Juhani, Laukkarinen, Johanna, Tiikkainen, Mirja, Sirén, Jukka, Soinio, Minna, Nuutila, Pirjo, Moilanen, Leena, Laaksonen, David E, Ebeling, Tapani, Arola, Johanna, Schalin-Jäntti, Camilla, Jaatinen, Pia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784472/
https://www.ncbi.nlm.nih.gov/pubmed/34374651
http://dx.doi.org/10.1530/EJE-21-0230
_version_ 1784638747356168192
author Peltola, Elina
Hannula, Päivi
Huhtala, Heini
Metso, Saara
Sand, Juhani
Laukkarinen, Johanna
Tiikkainen, Mirja
Sirén, Jukka
Soinio, Minna
Nuutila, Pirjo
Moilanen, Leena
Laaksonen, David E
Ebeling, Tapani
Arola, Johanna
Schalin-Jäntti, Camilla
Jaatinen, Pia
author_facet Peltola, Elina
Hannula, Päivi
Huhtala, Heini
Metso, Saara
Sand, Juhani
Laukkarinen, Johanna
Tiikkainen, Mirja
Sirén, Jukka
Soinio, Minna
Nuutila, Pirjo
Moilanen, Leena
Laaksonen, David E
Ebeling, Tapani
Arola, Johanna
Schalin-Jäntti, Camilla
Jaatinen, Pia
author_sort Peltola, Elina
collection PubMed
description OBJECTIVE: Insulinomas are rare functional pancreatic neuroendocrine tumours. As previous data on the long-term prognosis of insulinoma patients are scarce, we studied the morbidity and mortality in the Finnish insulinoma cohort. DESIGN: Retrospective cohort study. METHODS: Incidence of endocrine, cardiovascular, gastrointestinal and psychiatric disorders, and cancers was compared in all the patients diagnosed with an insulinoma in Finland during 1980–2010 (n = 79, including two patients with multiple endocrine neoplasia type 1 syndrome), vs 316 matched controls, using the Mantel–Haenszel method. Overall survival was analysed with Kaplan–Meier and Cox regression analyses. RESULTS: The median length of follow-up was 10.7 years for the patients and 12.2 years for the controls. The long-term incidence of atrial fibrillation (rate ratio (RR): 2.07 (95% CI: 1.02–4.22)), intestinal obstruction (18.65 (2.09–166.86)), and possibly breast (4.46 (1.29–15.39) and kidney cancers (RR not applicable) was increased among insulinoma patients vs controls, P  < 0.05 for all comparisons. Endocrine disorders and pancreatic diseases were more frequent in the patients during the first year after insulinoma diagnosis, but not later on. The survival of patients with a non-metastatic insulinoma (n = 70) was similar to that of controls, but for patients with distant metastases (n = 9), the survival was significantly impaired (median 3.4 years). CONCLUSIONS: The long-term prognosis of patients with a non-metastatic insulinoma is similar to the general population, except for an increased incidence of atrial fibrillation, intestinal obstruction, and possibly breast and kidney cancers. These results need to be confirmed in future studies. Metastatic insulinomas entail a markedly decreased survival.
format Online
Article
Text
id pubmed-8784472
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-87844722022-01-26 Long-term morbidity and mortality in patients diagnosed with an insulinoma Peltola, Elina Hannula, Päivi Huhtala, Heini Metso, Saara Sand, Juhani Laukkarinen, Johanna Tiikkainen, Mirja Sirén, Jukka Soinio, Minna Nuutila, Pirjo Moilanen, Leena Laaksonen, David E Ebeling, Tapani Arola, Johanna Schalin-Jäntti, Camilla Jaatinen, Pia Eur J Endocrinol Clinical Study OBJECTIVE: Insulinomas are rare functional pancreatic neuroendocrine tumours. As previous data on the long-term prognosis of insulinoma patients are scarce, we studied the morbidity and mortality in the Finnish insulinoma cohort. DESIGN: Retrospective cohort study. METHODS: Incidence of endocrine, cardiovascular, gastrointestinal and psychiatric disorders, and cancers was compared in all the patients diagnosed with an insulinoma in Finland during 1980–2010 (n = 79, including two patients with multiple endocrine neoplasia type 1 syndrome), vs 316 matched controls, using the Mantel–Haenszel method. Overall survival was analysed with Kaplan–Meier and Cox regression analyses. RESULTS: The median length of follow-up was 10.7 years for the patients and 12.2 years for the controls. The long-term incidence of atrial fibrillation (rate ratio (RR): 2.07 (95% CI: 1.02–4.22)), intestinal obstruction (18.65 (2.09–166.86)), and possibly breast (4.46 (1.29–15.39) and kidney cancers (RR not applicable) was increased among insulinoma patients vs controls, P  < 0.05 for all comparisons. Endocrine disorders and pancreatic diseases were more frequent in the patients during the first year after insulinoma diagnosis, but not later on. The survival of patients with a non-metastatic insulinoma (n = 70) was similar to that of controls, but for patients with distant metastases (n = 9), the survival was significantly impaired (median 3.4 years). CONCLUSIONS: The long-term prognosis of patients with a non-metastatic insulinoma is similar to the general population, except for an increased incidence of atrial fibrillation, intestinal obstruction, and possibly breast and kidney cancers. These results need to be confirmed in future studies. Metastatic insulinomas entail a markedly decreased survival. Bioscientifica Ltd 2021-09-01 /pmc/articles/PMC8784472/ /pubmed/34374651 http://dx.doi.org/10.1530/EJE-21-0230 Text en © The authors https://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. (https://creativecommons.org/licenses/by/4.0/)
spellingShingle Clinical Study
Peltola, Elina
Hannula, Päivi
Huhtala, Heini
Metso, Saara
Sand, Juhani
Laukkarinen, Johanna
Tiikkainen, Mirja
Sirén, Jukka
Soinio, Minna
Nuutila, Pirjo
Moilanen, Leena
Laaksonen, David E
Ebeling, Tapani
Arola, Johanna
Schalin-Jäntti, Camilla
Jaatinen, Pia
Long-term morbidity and mortality in patients diagnosed with an insulinoma
title Long-term morbidity and mortality in patients diagnosed with an insulinoma
title_full Long-term morbidity and mortality in patients diagnosed with an insulinoma
title_fullStr Long-term morbidity and mortality in patients diagnosed with an insulinoma
title_full_unstemmed Long-term morbidity and mortality in patients diagnosed with an insulinoma
title_short Long-term morbidity and mortality in patients diagnosed with an insulinoma
title_sort long-term morbidity and mortality in patients diagnosed with an insulinoma
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784472/
https://www.ncbi.nlm.nih.gov/pubmed/34374651
http://dx.doi.org/10.1530/EJE-21-0230
work_keys_str_mv AT peltolaelina longtermmorbidityandmortalityinpatientsdiagnosedwithaninsulinoma
AT hannulapaivi longtermmorbidityandmortalityinpatientsdiagnosedwithaninsulinoma
AT huhtalaheini longtermmorbidityandmortalityinpatientsdiagnosedwithaninsulinoma
AT metsosaara longtermmorbidityandmortalityinpatientsdiagnosedwithaninsulinoma
AT sandjuhani longtermmorbidityandmortalityinpatientsdiagnosedwithaninsulinoma
AT laukkarinenjohanna longtermmorbidityandmortalityinpatientsdiagnosedwithaninsulinoma
AT tiikkainenmirja longtermmorbidityandmortalityinpatientsdiagnosedwithaninsulinoma
AT sirenjukka longtermmorbidityandmortalityinpatientsdiagnosedwithaninsulinoma
AT soiniominna longtermmorbidityandmortalityinpatientsdiagnosedwithaninsulinoma
AT nuutilapirjo longtermmorbidityandmortalityinpatientsdiagnosedwithaninsulinoma
AT moilanenleena longtermmorbidityandmortalityinpatientsdiagnosedwithaninsulinoma
AT laaksonendavide longtermmorbidityandmortalityinpatientsdiagnosedwithaninsulinoma
AT ebelingtapani longtermmorbidityandmortalityinpatientsdiagnosedwithaninsulinoma
AT arolajohanna longtermmorbidityandmortalityinpatientsdiagnosedwithaninsulinoma
AT schalinjantticamilla longtermmorbidityandmortalityinpatientsdiagnosedwithaninsulinoma
AT jaatinenpia longtermmorbidityandmortalityinpatientsdiagnosedwithaninsulinoma